Table 4.
Effects of clinically established drugs and CXL-1020 when administered in combination on estimated mechanical energy and LV hemodynamics indices in instrumented anesthetized normal rats.
| Parameters | Drug | Normal | ||
|---|---|---|---|---|
| Baseline | Drug | % Δ from baseline | ||
| MAP (mmHg) | CXL-1020 | 123 ± 4 | 92 ± 9* | −26 ± 6 |
| CXL-1020 + ENA | – | 69 ± 9 | −44 ± 7# | |
| CXL-1020 | 114 ± 5 | 85 ± 5* | −26 ± 4 | |
| CXL-1020 + MET | – | 67 ± 5 | −41 ± 5# | |
| CXL-1020 + DOB | – | 81 ± 6 | −29 ± 5 | |
| PVA (mmHg * RVU * 103) | CXL-1020 | 2.7 ± 0.5 | 1.9 ± 0.3* | −28 ± 6 |
| CXL-1020 + ENA | – | 1.7 ± 0.3* | −33 ± 5 | |
| CXL-1020 | 3.9 ± 0.6 | 2.5 ± 0.4* | −37 ± 7 | |
| CXL-1020 + MET | – | 2.4 ± 0.3* | −43 ± 6 | |
| CXL-1020 + DOB | – | 4.5 ± 0.7* | 24 ± 16# | |
| PRSW (mmHg) | CXL-1020 | 56 ± 11 | 79 ± 8 | 56 ± 10 |
| CXL-1020 + ENA | – | 76 ± 5 | 56 ± 20 | |
| CXL-1020 | 48 ± 5 | 73 ± 11 | 51 ± 15 | |
| CXL-1020 + MET | – | 64 ± 6 | 39 ± 19 | |
| CXL-1020 + DOB | – | 114 ± 9 | 125 ± 20# | |
Summary data as % change from baseline of CXL-1020 administered with an ACE inhibitor, (ENA, 1 mg/kg/h, n = 5), β-AR blocker, MET (1 mg/kg/h, n = 7), and β-AR 1 agonist, DOB (5 μg/kg/min, n = 7).
*
P < 0.05 vs. corresponding baseline,
#
P < 0.05 vs. corresponding CXL-1020 alone.